Skip to content
Companies

Corami Biotech

Catheter-placed gels that deliver drugs to the heart

Raised to date

$230K

of $1M offered across 1 Form D filing

Still open
$770K
Investors
3
Last filed
Apr 22, 2026

About

Corami Biotech is a preclinical-stage cardiac biotechnology company based in Memphis, Tennessee, developing a platform for targeted delivery of therapeutics to the heart. Its approach uses a catheter-based device to place therapeutic gels directly on the surface of the heart, so treatment is localized to cardiac tissue rather than delivered systemically. The company's stated first indication is atrial fibrillation. It was incorporated in 2024 and is led by CEO Esra Roan, PhD, with founder Rebecca Levit, MD chairing the clinical advisory board.

Localized, sustained delivery of therapeutics directly to the heart surface, aiming to give cardiac tissue a sustained dose while limiting the systemic side effects of conventional delivery.

Funding

  • Option to acquireFiled Apr 22, 2026Form D
    $230K/ $1M

Product

Targeted cardiac therapeutic delivery platform

Medical device / drug delivery platform

A catheter-delivered platform that places therapeutic gels directly onto the surface of the heart for localized, sustained treatment of cardiac disease.

  • Catheter-based placement of therapeutic gel on the heart surface
  • Localized delivery to cardiac tissue
  • Sustained dosing at the treatment site

Built for

Cardiologists and cardiac care providers treating heart disease patients, initially those with atrial fibrillation

People on file